Abbott Laboratories (NYSE:ABT) Shares Sold by White Pine Capital LLC

White Pine Capital LLC lowered its position in Abbott Laboratories (NYSE:ABT) by 11.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,448 shares of the healthcare product maker’s stock after selling 2,511 shares during the period. White Pine Capital LLC’s holdings in Abbott Laboratories were worth $2,141,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ABT. Connecticut Wealth Management LLC grew its holdings in Abbott Laboratories by 68.8% during the 3rd quarter. Connecticut Wealth Management LLC now owns 6,808 shares of the healthcare product maker’s stock valued at $659,000 after buying an additional 2,776 shares during the last quarter. TFG Advisers LLC grew its holdings in Abbott Laboratories by 4.5% during the 3rd quarter. TFG Advisers LLC now owns 6,300 shares of the healthcare product maker’s stock valued at $610,000 after buying an additional 271 shares during the last quarter. Investment Advisory Services Inc. TX ADV grew its holdings in Abbott Laboratories by 0.7% during the 3rd quarter. Investment Advisory Services Inc. TX ADV now owns 23,436 shares of the healthcare product maker’s stock valued at $2,270,000 after buying an additional 154 shares during the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO grew its holdings in Abbott Laboratories by 1.0% during the 3rd quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 41,981 shares of the healthcare product maker’s stock valued at $4,066,000 after buying an additional 421 shares during the last quarter. Finally, Campbell Newman Asset Management Inc. grew its holdings in Abbott Laboratories by 0.4% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 136,829 shares of the healthcare product maker’s stock valued at $13,252,000 after buying an additional 515 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.6 %

NYSE:ABT traded up $0.67 during mid-day trading on Friday, reaching $107.53. The stock had a trading volume of 3,575,566 shares, compared to its average volume of 5,219,304. The company has a market capitalization of $186.58 billion, a price-to-earnings ratio of 33.50, a price-to-earnings-growth ratio of 2.57 and a beta of 0.74. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The stock’s 50 day simple moving average is $113.64 and its two-hundred day simple moving average is $108.03. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. The business had revenue of $9.96 billion during the quarter, compared to the consensus estimate of $9.88 billion. During the same period last year, the firm earned $1.03 earnings per share. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. Equities analysts anticipate that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, April 12th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.05%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 68.54%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Raymond James restated a “buy” rating and set a $124.00 price objective on shares of Abbott Laboratories in a report on Wednesday. Citigroup raised their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Royal Bank of Canada decreased their price objective on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday, April 18th. Evercore ISI increased their target price on Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, Barclays cut their target price on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research report on Monday, April 22nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $121.50.

Insider Activity

In other news, VP John A. Jr. Mccoy sold 472 shares of Abbott Laboratories stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the sale, the vice president now owns 18,760 shares of the company’s stock, valued at $2,223,060. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Andrea F. Wainer sold 42,500 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the sale, the executive vice president now owns 65,027 shares of the company’s stock, valued at $7,315,537.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the sale, the vice president now directly owns 18,760 shares in the company, valued at approximately $2,223,060. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,435 shares of company stock valued at $6,451,298. Insiders own 1.10% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.